Sign In
Buy FHTX
$3.64
+0.0100 (+0.275%)
At Close: Jun 03, 2026
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
04:05pm, Thursday, 06'th Mar 2025
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the prima
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know
11:06am, Thursday, 27'th Feb 2025
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
07:00am, Tuesday, 25'th Feb 2025
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
10:26am, Tuesday, 11'th Feb 2025
Foghorn Therapeutics (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Wednesday, 15'th Jan 2025
Foghorn Therapeutics (FHTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earning
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Thursday, 09'th Jan 2025
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
07:00am, Monday, 16'th Dec 2024
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficac
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)
10:36am, Thursday, 12'th Dec 2024
The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
01:00pm, Friday, 29'th Nov 2024
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?
10:56am, Monday, 25'th Nov 2024
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
07:54am, Tuesday, 12'th Nov 2024
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
06:31pm, Monday, 04'th Nov 2024
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago.
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
04:05pm, Monday, 04'th Nov 2024
First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC
Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn's selective SMARCA2 oncology p
Foghorn Therapeutics to Participate in the BMO Oncology Summit
07:00am, Tuesday, 01'st Oct 2024
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
